Lower Respiratory Tract Therapeutics Market Report 2025

The lower respiratory tract therapeutics market size has grown strongly in recent years. It will grow from $36.03 billion in 2024 to $38.98 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to antibiotic discoveries, vaccination programs, smoking cessation campaigns, advancements in inhalation therapy, healthcare infrastructure growth.

The lower respiratory tract therapeutics market size is expected to see strong growth in the next few years. It will grow to $53.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising air pollution levels, aging population, antimicrobial resistance, environmental factors. Major trends in the forecast period include precision medicine approaches, technological innovation, biologic therapies, telehealth in respiratory care, personalized inhalation devices.

The escalating occurrence of respiratory ailments is poised to significantly bolster the lower respiratory tract therapeutics market in the forthcoming period. Respiratory illnesses encompass a range of medical conditions impacting the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Lower respiratory tract therapeutics play a pivotal role in the early identification and diagnosis of these conditions, enabling timely intervention and management. This proactive approach aids in halting disease progression, controlling the spread of infectious respiratory diseases, and mitigating the likelihood of complications. As per data reported in September 2022 by the NCD Alliance, a civil society organization based in Switzerland, lung cancer stood as the leading cause of global cancer-related deaths, foreseeing an annual estimate of 2.2 million new cases and 1.8 million fatalities. Furthermore, chronic respiratory disorders impacted 550 million adults worldwide, resulting in 4.2 million deaths, constituting 7% of all mortalities. Thus, the escalating prevalence of respiratory diseases is set to act as a major impetus driving the growth of the lower respiratory tract therapeutics market.

The rising prevalence of smoking is anticipated to drive the growth of the lower respiratory tract therapeutics market in the future. Smoking involves inhaling and exhaling the smoke from burning tobacco or other substances. Lower respiratory tract therapeutics are used to alleviate inflammation, reduce symptoms, slow disease progression, improve airflow and lung function, decrease the frequency and severity of exacerbations, enhance oxygen levels, and increase the likelihood of successful smoking cessation. For instance, in July 2023, a report from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that tobacco use kills over 8 million people annually, including 1.3 million non-smokers exposed to second-hand smoke. Consequently, the growing prevalence of smoking is fueling the expansion of the lower respiratory tract therapeutics market.

Product innovations are a key trend in the lower respiratory tract therapeutics market. Leading companies in this market are introducing new and innovative products to enhance their market position. For example, in November 2022, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, and Sanofi S.A., a France-based pharmaceutical firm, launched Beyfortus to prevent lower respiratory tract disease in newborns and infants. This medicine has been approved by the European Union (E.U.) to prevent respiratory syncytial virus (RSV) and lower respiratory tract illnesses in newborns and infants during their first RSV season. Beyfortus is the first single-dose RSV passive immunization designed for the general newborn population, including healthy, full-term, premature babies, and those with special medical conditions.

Major players operating in the lower respiratory tract therapeutics market are concentrating on innovative offerings such as triple combination drugs tailored for COPD management to bolster their market revenues. This triple combination therapy for COPD comprises long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS) as the three primary inhaled medications. For instance, Lupin Limited, a pharmaceutical company based in India, introduced Vilfuro-G in November 2023. Vilfuro-G, available in a fixed dosage strength with once-daily dosing recommendations, is poised to significantly enhance the lives of COPD patients. This launch demonstrates Lupin's commitment to expanding its respiratory product line and providing healthcare professionals and patients with state-of-the-art treatment alternatives. Notably, Vilfuro-G stands as the only fixed-dose combination specifically formulated to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.

In June 2022, Pfizer Inc., a prominent US-based pharmaceutical and biotechnology company, successfully acquired ReViral for an undisclosed amount. Through this acquisition, Pfizer seeks to broaden its portfolio of potential treatment options, with a particular focus on sisunatovir. Sisunatovir is an orally administered inhibitor specifically designed to prevent the respiratory syncytial virus (RSV) from attaching to the host cell's membrane. ReViral Ltd., the UK-based biopharmaceutical company that Pfizer acquired, is known for its dedication to developing novel antiviral therapeutics with a focus on targeting respiratory syncytial virus.

Major companies operating in the lower respiratory tract therapeutics market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Menarini Group, Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Orion Corporation, Sunovion Pharmaceuticals Inc., Innoviva Inc., Insmed Incorporated, Vectura Group plc, Theravance Biopharma Inc., Verona Pharma plc, Circassia Pharmaceuticals plc.

North America was the largest region in the lower respiratory tract therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lower respiratory tract therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lower respiratory tract therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The lower respiratory tract constitutes the segment of the respiratory system responsible for the exchange of gases, wherein oxygen is taken in, and carbon dioxide is expelled. Lower respiratory tract therapeutics is a specialized field within medical science and clinical practice that is dedicated to the diagnosis, treatment, and management of diseases and disorders affecting the lower respiratory tract. These therapeutic interventions aim to enhance the quality of life and overall health outcomes for individuals grappling with lower respiratory tract disorders.

The primary disease types addressed by lower respiratory tract therapeutics include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis, bronchitis, and others. Asthma, for instance, is a chronic respiratory disorder characterized by inflammation of the airways, resulting in their narrowing and leading to frequent bouts of coughing, wheezing, chest tightness, and shortness of breath. Various drug classes are employed in lower respiratory tract therapeutics, including antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), cough suppressants, nasal decongestants, and others. These therapeutics are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, providing individuals with access to the necessary medications for managing lower respiratory tract conditions.

The lower respiratory tract therapeutics market research report is one of a series of new reports that provides lower respiratory tract therapeutics market statistics, including lower respiratory tract therapeutics industry global market size, regional shares, competitors with lower respiratory tract therapeutics market share, detailed lower respiratory tract therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the lower respiratory tract therapeutics industry. This lower respiratory tract therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lower respiratory tract therapeutics market consists of sales of beta-lactam antibiotics, macrolides, and fluoroquinolones. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.